Structured evidence table for Ashwagandha Fatigue Randomized Trial, generated from 1 reusable source document in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Ashwagandha Fatigue Randomized Trial | Although its safety at conventional doses is well established, evidence regarding the safety of higher doses in healthy adults remains limited. | 4 | Movva N (2026) | Safety and tolerability of Ashwagandha (<i>Withania somnifera</i>) root extract in healthy adults: a prospective, non-comparative study. |
| Ashwagandha Fatigue Randomized Trial | All values remained within reference ranges and were clinically insignificant, with most values slightly reduced except a small increase in alkaline phosphatase. | 4 | Movva N (2026) | Safety and tolerability of Ashwagandha (<i>Withania somnifera</i>) root extract in healthy adults: a prospective, non-comparative study. |
| Ashwagandha Fatigue Randomized Trial | Quality of life (SF-36 scores) demonstrated improvement ( p Conclusion High-dose Ashwagandha root extract (2000 mg/day) was well tolerated and demonstrated a favourable safety profile in healthy adults over 12 weeks. | 4 | Movva N (2026) | Safety and tolerability of Ashwagandha (<i>Withania somnifera</i>) root extract in healthy adults: a prospective, non-comparative study. |
| Ashwagandha Fatigue Randomized Trial | Background and aim Ashwagandha, adaptogenic herb traditionally used to enhance resilience to stress and promote overall well-being. | 4 | Movva N (2026) | Safety and tolerability of Ashwagandha (<i>Withania somnifera</i>) root extract in healthy adults: a prospective, non-comparative study. |
Source documents